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ABSTRACT
DESIGNING A PORE-FORMING TOXIN CYTOLYSIN A (CLYA) TO TARGET
CANCER CELLS

SEPTEMBER 2014
ALZIRA R.M. AVELINO, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Dr. Min Chen
Cytolysin A (ClyA) is a member of a class of proteins called pore-forming toxins
(PFTs). ClyA is secreted by Gram-negative bacteria, and it attacks a number of
mammalian cells by inserting into and forming channels within the cell
membrane (Oscarsson J et al., 1999). It has been suggested that ClyA binds to
cholesterol (Oscarsson J et al., 1999) and thus can insert into the membranes of
many different cell types of eukaryotic origin. In our studies we propose to
engineer a ClyA protein that can only attack a small subset of cell types. We
propose to engineer ClyA that can be only activated when exposed to specific
cell-surface proteases produced by a specific cell type. We ultimately want to
target breast cancer cells that differentially secrete or express proteases such as
matrix-metalloproteases (Stautz D et al., 2012; Zhang, M et al. 2013). To
engineer this protein we took advantage of the N-terminus of ClyA. The Nterminus of ClyA, which is highly hydrophobic (Oscarsson J et al), undergoes a
conformational change to insert into the target cell membrane (Oscarsson J et
al). This conformational change allows ClyA to penetrate the target membrane
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to form a transmembrane domain of ClyA. The hydrophobic nature of lipid
membranes makes it highly unfavorable for any charged residues to cross the
membrane (Hunt J 1997). With this in mind, we hypothesize that negative
charges inserted into the N-terminus of ClyA will inhibit it from inserting into the
membrane. Thus, we mutated the N-terminus of the ClyA protein by inserting an
inactivation site composed of negatively charged amino acids that we
hypothesize would prevent insertion into the plasma membrane of the target
cell. Once we confirmed that this construct was an inactive ClyA mutant, we
inserted a thrombin cleavage site right after the inserted negative charges. This
site should allow us to remove the negative charges once the protein is exposed
to thrombin. Once the negative charges are removed, the protein should recover
its activity. This approach will allow us to create a version of ClyA that is
protease-switchable
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CHAPTER 1
INTRODUCTION
1.1 Cytolysin A (ClyA) as a potential cancer therapeutic
Finding new treatments for cancer has been one of the top priorities of many
research laboratories. There have been many treatments such as chemotherapy
and radiation therapy that have been shown to be effective. However, these
treatments have many side effects. These treatments often attack rapidly
replicating cells in a non-specific manner, and there is always a chance of
disease reoccurrence. For this reason it is necessary to develop new treatments
that are more effective and specific (Hassan et al., 2010).
New developments combine current therapies with bacterial therapy (BT).
Studies have shown that bacteria such as Escherichia coli (E. coli) accumulate in
tumors (Chen D et al, 2010; Kim J. et al. 2008; Anderson, J. C. et al. 2006), and
we can use this characteristic to deliver specific anti-tumor treatments.
1.2 Cytolysin A (ClyA)
Cytolysin A (ClyA) is a pore-forming protein secreted by Gram-negative bacteria
such as E. coli and Salmonella enterica, serova, typhi and Paratyphi A (Jiang S.
et al., 2010; Von Rhein, C. et al, 2009). The shape of ClyA is a long rod, and it is
comprised of 81% α-helices and 2% β strands (Wallace et al., 2000). It is a 34
kDa protein that is cytotoxic to cultured mammalian cells and can also cause
macrophage apoptosis (Jiang S., 2010). ClyA is transported from the bacteria to
the target cell in outer membrane vesicles (OMVs) as an oligomer (Chen et. al,
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2008). Once ClyA reaches the target membrane, the N-terminus (Figure 1a in
red) undergoes a conformational change and inserts into the membrane (Figure
1b). ClyA is made as a soluble monomer and exported to the periplasm (Chen et.
al, 2008). To form into an active pore, the protein oligomerizes into a dodecamer
Chen et. al, 2008) (Figure 1b) that has a diameter of 35 Å at its narrowest
opening and 70 Å at the top of the oligomer (Mueller M. et al., 2009). The X-ray
crystal structure of the monomer was solved by Wallace et al. (Wallace AJ. et al
2000 Cell), and the oligomer crystal structure was solved by Mueller et al.
(Mueller M. et al., 2009).
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Figure 1: Schematic representation of ClyA molecules. (a) Representation
of an inactive monomer, with the N-terminus tucked in; (b) The active protomer
with the N-terminus inserted into a target lipid membrane. In a and b, the Nterminus is highlighted in red. Structures were drawn in PyMol.
The toxic ClyA pore shown in Figure 1b promotes lysis of the target cell by
allowing uncontrollable exchange of materials between the extracellular
environment and the intracellular contents.
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CHAPTER 2
RESULTS AND DISCUSSION
2.1 Construct design
To make a switchable form of ClyA, we took advantage of its N-terminus,
which is responsible for its membrane insertion. The N-terminus of ClyA crosses
the target lipid membrane and forms a transmembrane domain. By mutating the
N-terminus, we can prevent the membrane insertion.
Charged residues are very energetically unfavorable to cross the cell
membrane (Hunt J 1997). Moreover, we hypothesize that negative charges are
even more unfavorable because the phospholipid heads that are also negatively
charged should repel the negative residues on ClyA. Therefore, we hypothesized
that negative charges added to the N-terminus will inhibit ClyA insertion into a
target membrane.
To accomplish this, we designed mutant ClyA proteins that contain
stretches of negatively charged amino acids (aspartate and/or glutamate) and
tested the activity of these modified proteins with hemolytic assays, where we
mix the ClyA proteins with erythrocytes and if lysis occurs hemoglobin is released
and quantified with the use of a spectrophotometer (540 nm). For more detail,
refer to Appendix A. Initially our constructs contained negative charges added at
the N-terminus and a hexa-histidine tag (His-tag) at the C-terminus. Later, the
His-tag was moved from the C-terminus to the N-terminus in modified constructs.

	
  
	
  

3	
  

To make the mutant ClyA a switchable protein, we also designed constructs with
a protease (thrombin) cleavage site directly after the negative charges. If
exposed to protease (thrombin), the negatively charged amino acids could then
be cleaved off and the ClyA protein reactivated. Figure 2 summarizes the
designed constructs.

Figure 2: Protein representation of the designed mutant versions of ClyA.
The figure above describes the location of the inactivating site (red), comprised of
varying numbers of aspartates (Asp) and/or glutamates (Glu), the His-tag (blue)
and the thrombin cleavage site (yellow). ClyA is indicated in gradient black.

2.2 Purification of the inactive mutant proteins
All of the constructs were purified using nitrilotriacetic acid affinity
chromatography (Ni-NTA) purification, which takes advantage of specific binding
between the His-tag and nickel immobilized in the chromatography column
(Figure 3). To further purify ClyA, we used gel filtration chromatography (GFC)
that separated molecules according to their stochastic radius. Whereas a
monomer of ClyA will elute with buffer at a volume of 15 ml using Superdex 200,
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the mutant proteins elute at 17 ml of retention volume (Fig. 4). For more
information on this technique, refer to Appendix A.

	
  
Figure 3: Nickel affinity chromatography of His-tagged ClyA. Graph in black
represents absorbance of protein at 280 nm and the graph in red is the
percentage of 0.5 M imidazole in the elution buffer. ClyA starts to elute at just
under 20% 0.5 M imidazole. The light blue bar represents where the ClyA
monomer was collected.

	
  
Figure 4: Gel filtration chromatogram of ClyA monomer. The pure, negatively
charged ClyA mutants elute around 17 ml. The red bar represents where the
ClyA monomer was collected.
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2.3 Testing the activity of purified samples
To test the activity of the ClyA putatively inactive mutants, we use a liquid
hemolytic assay (Fahie, M. et al. 2013; Rowe, G. C. et al.1994). ClyA can lyse
erythrocytes, thus releasing hemoglobin that can be quantified by measuring its
innate absorbance at 540 nm (Iwasaka, M., et al. 2001). The absorbance value
and the release of hemoglobin directly correlate with the number of erythrocytes
lysed and thus how active the protein (ClyA) is. Refer to Appendix A for details on
how the experiment was performed.
Figure 5 below shows the activity of the mutant ClyA using construct 1
from Figure 2, with different numbers of negative charges. At 6, 10, 12, 15, or 18
negative charges (aspartates and glutamates) the activity of ClyA was not
completely inhibited, as indicated by 60% lysis or higher. These findings led us
to increase the number of negative charges up to 24 (Figures 5 and 6).
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Figure 5: Hemolytic activity of ClyA mutants. Constructs with increasing
numbers of negative charges (6-cyan,10-blue,12-navy,15-gray,18-black)
designed from construct 1 (Figure 2) were tested. All samples had a protein
concentration of 0.7 μg/ml. From the above figures, we can see how various
numbers of negative charges affect the activity of ClyA. All samples were
incubated with defibrinated sheep red blood cells at 370C for 15 minutes. WT:
wild-type ClyA, without additional negative charges.
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Figure 6: Hemolytic activity of mutant ClyA proteins with larger numbers of
negative charges. Twenty-one negative charges (cyan) and 24 negative
charges (dark blue) from construct 1 (Figure 2) and WT ClyA (white) with a Cterminal His-tag were tested. All samples had a protein concentration of 0.6
μg/ml. From the above figures we can see how various numbers of negative
charges affect the activity of ClyA. All samples were incubated with defibrinated
sheep red blood cells at 370C for 15 minutes.
Even with increasing numbers of negative amino acids, the activity of ClyA
was still very high. This result suggests that either 24 negative charges can
comfortably cross a bilayer, or that we are not working with the expected
construct. However, as mentioned earlier, it is highly unfavorably to insert 24
negative charges across a bilayer (Hunt J 1997). To distinguish between the
possible explanations, we moved the His-tag from the C-terminus to the Nterminus directly before the negative charges (construct 2, Figure 2). This allows
only the correct mutant protein to be selected by nickel affinity purification.
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Figure 7 below shows the activity of the mutant ClyA with different
numbers of negative charges and with an N-terminal His-tag (Nhis).

	
  
Figure 7: Hemolytic activity of mutant ClyA proteins with different numbers
of negative charges and an N-terminal His-tag. 6-Nhis is ClyA with six
additional negative charges and an N-terminal His-tag, 12-Nhis has 12 negative
charges and an N-terminal His-tag, and 18-Nhis has 18 negative charges and an
N-terminal His-tag. All samples had a protein concentration of 4.4 μg/ml. The
negative control in black contains blood with no protein added. From the above
figure we can see how much each number of negative charges with an Nterminal His-tag affected the activity of ClyA. All samples were incubated with
defibrinated sheep red blood cells at 370C for 15 minutes.
	
  
The hemolytic assay shows that with 12 and 18 negative charges after the
N-terminal His-tag, the activity of ClyA is increasingly inhibited. Because of this
result, we concluded that the mutants based on construct 1 were being posttranslationally cleaved to wild type (WT)-like-ClyA.
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2.4 Making a switchable ClyA
The next step is to introduce a thrombin cleavage site just after the
negative charges so that when thrombin is present it can cleave the negative
charges, thus reactivating ClyA (construct 3, Figure 2).
After purification with GFC and confirming that we had obtained the pure
mutant protein by performing sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) (Figure 8), the new mutant protein with the
thrombin cleavage site and 18 negative charges (18-NhisT) was incubated with
thrombin in a cleavage assay and its activity tested (Figure 9). For more
information on the thrombin cleavage assay see Appendix A. The expected size
of ClyA is 34 kDa. However, the mutants with N-terminal negative charges seem
to travel further down the SDS-PAGE gel. We hypothesize that the negative
charges may be the cause of this migration pattern, since the additional negative
charges in the mutant proteins may make them more strongly attracted to the
positive electrode during SDS-PAGE (Figure 8). The WT ClyA band intensity is
stronger than the band intensities for the negative mutants, because the
purification with nickel columns yields a lower concentration of negative mutant.
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Figure 8: SDS-PAGE of purified proteins after GFC. 18-Thr-ClyA is the mutant
ClyA with 18 negative charges, thrombin cleavage site and N-terminal His-tag.
18-ClyA lacks the thrombin cleavage site. WTClyA has an N-terminal His-tag, but
no additional negatively charged residues.

11	
  

	
  

	
  	
  
	
  Figure 9: Hemolytic assay of the mutant 18-thr-ClyA protein with N-terminal
His-tag. One mole of wild-type or mutant ClyA (18-NhisT) was incubated with 2.5
moles of thrombin overnight at room temperature. All samples had a protein
concentration of 4.4 μg/ml. Then the samples were incubated with red blood cells
for 15 minutes at 370C to test for hemolytic activity (WTClyA Nhis-tag in gray, 18thr-ClyA in white with vertical stripes. 18-thr-ClyA in black indicates the mutant
with no thrombin added, and the cyan bar represents thrombin incubated with
blood with no other protein added).

The activity assay of Fig. 9 showed that thrombin treatment did not restore
the mutant’s activity, leading us to question whether the thrombin site was
accessible to thrombin. Thus, we inserted a longer glycine linker between the
inactivating site and the cleavage site (Figure 2, construct 3); the insertion of this
type of linker has been shown to improve the cleavage site’s accessibility to
thrombin (Hakes, D. et al, 1992).
12	
  

	
  

After obtaining and purifying the constructs with longer G-linkers (from 1
glycine to 6 glycines) named 12-NhisT and 18-NhisT (construct 3, Figure 2), the
hemolytic activity of the constructs was once again tested after incubation without
and with thrombin (Fig. 10).

	
  	
  
Figure 10: Hemolytic assay of 12-NhisT and 18-NhisT with a hexa-glycine
linker. The samples were incubated with thrombin in a 1:3.5 molar ratio
overnight at room temperature. Then the samples were incubated with red blood
cells for 15 minutes at 37°C. The concentration of protein present in all the
samples was 10.5 μg/ml. The negative control in white just contains erythrocytes
in buffer with no added protein. WTNhis ClyA in black is the positive control; 12NhisT in dark gray with oblique strips is the ClyA mutant with 12 negative
charges, thrombin cleavage site and N-terminal His-tag. 18-NhisT differs from the
previous construct (12-NhisT) only in the fact that it contains 18 N-terminal
negative charges.

From Figure 10, we conclude that the longer glycine linker has improved
the accessibility of the cleavage site to thrombin, because when these ClyA
13	
  

	
  

mutant proteins were incubated with thrombin, the percent of lysis had a 30%
increase for 18-NhisT, and for 12-NhisT to almost WT status. Although after
thrombin treatment 12-NhisT2 regained high activity, this protein is still active
(~24% lysis) when thrombin is not present.

Ideally, we want to design a

switchable ClyA that is completely inactive without thrombin treatment even at
high protein concentrations of the ClyA construct, which is the case for 18-NhisT.
This latter mutant has very low activity, approximately 2%, in the absence of
thrombin, but when thrombin is present the hemolytic activity of 18-NhisT
increases to approximately 30%. However this activity increase is still not ideal.
Ideally we would want a hemolytic activity increase to 80% or more. A shorter
incubation period at 37°C would also be preferable (4 hours or less) and a molar
ratio of at least 30:1 (ClyA protein to thrombin) is more desirable for medical
application. We ultimately want to be able to activate the switchable protein in a
short period of time and with a low concentration of protease, which we
hypothesize would mimic human biological conditions.
In this matter, new constructs are being designed in order to increase
activity when a specific protease is present and also to retain inactivity when the
specific protease is absent. Once the new constructs are tested and satisfy all of
these requirements, we will proceed to the next steps, which will be to design
metalloprotease cleavage sites into the optimal construct and perform activity
experiments with cultured mammalian cell lines.
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2.5 Mechanism of inhibition
We hypothesized that adding negative charges inhibits membrane
interaction, but activity can also be inhibited by preventing the oligomerization of
ClyA. The lack of activity of the mutant 18-Nhis could be due to an inefficient
membrane insertion or inefficient oligomerization, since the negative charges on
individual monomers may not only repel the phospholipid bilayer but also repel
each other. To test whether oligomerization was inhibited, we induced
oligomerization

with

the

commonly

used

detergent

n-dodecyl-ß-D-

maltoside (DDM). We used GFC to detect the various oligomerization states (see
Appendix A). According to the elution pattern, we can determine whether ClyA is
oligomerized or not. Elution of the protein earlier than 17 ml means that the
mutant can oligomerize into various forms such as dimers, etc., but if
oligomerization is disrupted, the protein will elute as a monomer around 15 ml or
17ml depending on whether it is a WT or mutant ClyA, respectively.
The mutant used for the oligomerization assay is 18-thr-ClyA (construct 3,
Figure 2). This mutant has 18 negative charges at its N-terminus and additionally
a thrombin cleavage site immediately after the negatively charged region.
Figure 11 shows GFC chromatograms of the elutions of the mutant (18thr-ClyA) and WT with the N-His-tag.
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Figure 11: GFC chromatograms of elutions of the different mutant proteins
with and without 0.1% DDM. After incubation with 0.1% DDM, the different
samples indicated above were run through GFC in buffer containing 0.01% DDM.
a) represents WT ClyA with no DDM added, b) shows the mutant with the 18
negative charges and N-His-tag with no DDM added. c) represents WT ClyA with
0.1% DDM added and incubated at 23°C for 30 minutes prior injection onto GFC,
and d) represents the 18-thr-ClyA mutant with the N-His tag prepared the same
way as in graph c. The y-axis represents absorbance at 280 nm (wavelength at
which protein absorbs light); the x-axis indicates the retention volume in ml.

According to Figure 11, the mutant 18Nhis cannot oligomerize into a
stable dodecamer (chromatogram d), because it still elutes after 15 ml of
acquired volume. The WTNhis ClyA forms stable oligomers when incubated with
0.1% DDM at 23°C and elutes as a monomer when not incubated with DDM (Fig.
11a).
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According to the data obtained thus far, we can conclude first that 18
negative charges at the N-terminus inhibit ClyA activity by inhibiting
oligomerization and second that thrombin cleavage with the optimized linker
restores the activity of this mutant. Further research is being performed in order
to optimize the percent recovery when appropriate protease is added.
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APPENDIX A
MATERIALS AND METHODS
Cloning strategy
All chemicals used were purchased from Fisher Scientific (Agawam, MA) unless
specified otherwise.
The negative mutants ClyA were cloned and amplified in a pT7 vector with a Cterminal or N-terminal His-tag. The polymerase chain reaction (PCR) was
performed using Phusion Polymerase (New England Biolabs, Ipswich, MA). The
PCR products were digested with DpnI to degrade the template DNA. The
digestion was performed for 3 hours at 37°C or overnight at the same
temperature. The DpnI product was then transformed into Escherichia coli (E.
coli) Nova Blue cells. The DNA sequence of the desired products was obtained
through DNA sequencing from the Genomics & Bioinformatics Facility (University
of Massachusetts Amherst, Amherst, MA). Refer to Table 1, Appendix B for the
list of primers and templates used.
Protein expression
To obtain the desired protein, we inoculated E. coli BL21 cells containing
the plasmid pT7-ClyA with the specific mutation into 1 L of Luria Broth (LB)
medium (Boston Bioproducts, Ashland, MA) containing 0.1 mg/ml of ampicillin.
The cells were grown at 37°C with shaking at 200 rpm to an OD600 of 0.6. Then
0.5 mM of Isopropyl β-D-1-thiogalactopyranoside was added to induce protein
expression. The culture was incubated overnight at 15°C.
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Protein purification
After expression, the cell culture was spun down for 30 minutes at 4000
rpm in a tabletop centrifuge. The supernatant was discarded and the pellet was
resuspended in 20 ml of 50 mM Tris-HCl, pH 8, 0.2 mg/ml lysozyme, 1 mM
ethylenediaminetetraacetic acid- EDTA, and 0.1 mM
phenylmethanesulfonylflouride (Sigma, St. Louis, MO). Then the lysate was
incubated for 30 minutes on ice. The lysate was then spun down for 30 minutes
at 13,000 rpm in a Sorvall RC 6 Plus centrifuge from Thermo Scientific (Waltham,
MA). The supernatant then was used for the following techniques.
The ClyA purification involves two chromatographic techniques: Ni-NTA
purification and gel filtration chromatography (GFC). For Ni-NTA purification, a
His-tag is introduced at the N-terminus or C-terminus of the protein. To do the
nickel purification, we used a column packed with beads that contain nickel
(Pierce centrifuge column, gravity column, from Thermo Scientific, Waltham, MA).
This column has a total volume of 4 ml. At the start of purification the column is
washed with 2 column volumes (CV) of 20% ethanol, 2 CV of miliQ water and 2
CV of Buffer A (150 mM NaCl, 50 mM Tris-HCl, pH 8). Tris was purchased from
Boston Bioproducts (Ashland, MA). After equilibrating the column with Buffer A,
the cell lysate is added and incubated with the nickel beads for 15 minutes on ice
with shaking. Then the lysate is allowed to pass through the column at a rate of
10 drops per minute. The rate can be controlled by capping the column, reducing
or increasing the airflow through the column. Only after the cell lysate has

19	
  

	
  

completely run through is 1 CV of Buffer A added to wash off unbound proteins.
Two more washing steps are conducted with Buffer A’ (150 mM NaCl, 50 mM
Tris-HCl, pH 8 and 10 mM imidazole from Thermo GE Healthcare) and Buffer A1
(150 mM NaCl, 50 mM Tris-HCl, pH 8 and 25 mM imidazole). Imidazole will
displace the protein of interest, which is collected in fractions. All fractions are
collected and run on a15% SDS-PAGE gel, containing 2,2,2-Trichloroethanol
(TCE), to determine which fraction has a higher concentration of pure ClyA using
the Gel DocTM imager from Bio RAD (Hercules, CA). The fraction with pure ClyA
is then dialyzed overnight (dialysis membrane from Spectra/Pro, MW cutoff 68000) in Buffer A (with EDTA) at 4°C. The second part of the purification involves
purification by GFC which separates proteins according to their stochastic radius.
For this type of chromatography we use the Superdex 200 column from CE
Healthcare (Piscataway, NJ). The column has a volume of 24 ml and elutes
soluble WT ClyA monomers at a 15 ml retention volume and elutes the
negatively charged mutants at a 17 ml retention volume. Initially the column is
washed with 2 CV of 20% ethanol and 2 CV of water, and then the column is
equilibrated with 2 CV of Buffer A. The dialyzed protein sample is concentrated to
1 ml using a Centricon from Millipore (Billerica, MA). Then the sample is injected
into the equilibrated column. Fractions are collected at the appropriate retention
volume and analyzed by SDS-PAGE (Figure 8) to determine the purity of the
sample. The protein concentration is determined with a Bicinchoninic acid (BCA)
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assay (kit from Thermo Scientific, Waltham, MA), and samples are stored at a
temperature of -80°C.
Hemolytic assay
To perform the hemolytic assays, we use defribinated sheep blood from Lampire
Biological Laboratories (Pipersville, PA). The blood is washed with milliQ water
containing 150 mM NaCl and centrifuged in a tabletop centrifuge from Eppendorf
(4,000 rpm, for 5 minutes) to pellet the red blood cells, the supernatant is
discarded, and the blood is diluted to 25% with milliQ water containing 150 mM
NaCl. There are two main controls for this experiment (positive and negative
control). The negative control is blood with buffer but no protein added, and the
positive control is 25% blood plus milliQ water brought up to the same volume
used in other samples. Twenty five percent blood is added to each sample and
the final volume of the protein solution depends on the desired protein
concentration (indicated in Figures 5, 6, 7, 9, and 10). The samples are incubated
at 37°C for 15 minutes; then the samples are centrifuged in a tabletop centrifuge
at 14,000 rpm for 2 minutes. The supernatant contains the hemoglobin released
from the cell, and its absorbance is measured at 540 nm. The absorbance values
are used to plot a graph indicating the percentage of lysis. The positive control
indicates 100% lysis while the negative control acts as a baseline for zero lysis.
Oligomerization assay
This experiment is performed to determine whether the mutant proteins, like WT
ClyA, can oligomerize in 0.1% n-Dodecyl β-D-maltoside (DDM). Seventy

21	
  

	
  

micrograms of protein is incubated with 0.1% DDM at 23°C (see Figure 7) for 30
minutes and then injected into the GFC column equilibrated with Buffer A
containing 0.01% DDM. The elution pattern is observed: if the protein elutes
before 15 ml of retention volume, it means that the protein can indeed form
various oligomers. However, if the protein elutes around 15-17 ml, it is eluting as
a monomer.
Thrombin cleavage assay
This assay is performed for mutant proteins that have a thrombin cleavage site. A
specific concentration of protein (see Figures 5, 6, 7, 9, and 10) is incubated with
thrombin (in a molar ratio indicated in the figure legend) overnight at room
temperature (approximately 23°C). After incubation, the samples are subjected to
a hemolytic assay to test if the activity is recovered. Thrombin is purchased from
MP Biomedicals (Santa Ana, CA).
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APPENDIX B
TABLE OF ALL MUTANTS AND PRIMERS
Table 1: List of all the negative mutants and primers used.
Negativ
e
mutant
ClyA
6-

Primers

Templa
te

FGATGATGACGATGACGACACTGA
AATCGTTGCAG

WTClyA
C-His
tag

Inserted
amino
acid
sequence

M-D6-ClyA

RGTCATCGTCATCATCCATCTCGA
GAGCCCA TATG

10-

FAGAGGAGGACGACGAAGAAGAT
ACTGAAATCGTTGCAG

6-

ME5D2E2DClyA

RTTCGTCGTCCTCCTCTTCTTCCT
CCATCTCGAGAGCCCATA

12-

FGAGGAGGAAGAGGAGACTGAAA
TCGTTGCAG

6M-D6E6ClyA

RCTCCTCTTCCTCCTCTTCGTCGT
CATCGTC
15-

FGAGGAGGATGACGAGACTGAAA
TCGTTGCAG
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12-

MD6E6D2EClyA

Purpose

Engineered
6-Aspartate
tag on
ClyA at the
N- terminus
to
Inhibit
membrane
insertion.
Engineered
6Aspartate,
2Glutamate
and 2Aspartate
tag on ClyA
N-terminus
to
inhibit
membrane
insertion
Engineered
6-Asp, 6Glu tag on
ClyA Nterminus to
inhibit
membrane
insertion
Insertion of
5 additional
negative
charges

RGTCTCGTCATCCTCCTCTTCCTC
CTCTTCG
18-

FGGATGACGAGGAGGAAGATACT
GAAATCGTTGCAG

15M-D6E6D2E
3D-ClyA

Insertion of
3 additional
negative
charges

M-D6E6D2E
3D3E-ClyA

Insertion of
3 additional
negative
charges

MD6E6D2E-C
3D3ED2EClyA

Insertion of
3 additional
negative
charges

M-H6inactive
site-ClyA

Insertion of
an Nterminal
Histag

R- TAT
CTTCCTCCTCGTCATCCTCCTCT
T CCTCCTC
21-

FGATGACGATGAAACTGAAATCGT
TGCAGAT

18-

RAGTTTCATCGTCATCTTCCTCCTC
GTC
24-

FACGATGAAGATGACGAGACTGAA
ATCGTTGCAG

21-

RGTCTCGTCATCTTCATCGTCATC
TTCCTCCTCGT
N-his
tag

FCACCATCATCACCACCATGATGA
TGACGATGAC

6-, 12-,
18-

RCATGGTGGTGATGATGGTGCATC
TCGAG AGCCCA
Thrombi
n site
insertion
12-

FCCTGGTGCCGCGTGGTAGCACT
GAAATCGTTGCA

12with an
N-His
tag

M-H6-D6E6GSLVPRSClyA

Insertion of
a thrombin
cleavage
site

18-

M-H6-

Insertion of

RCCACGCGGCACCAGGCTGCCCT
CCTCT TCCTCCTCT

Thrombi

F-
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n site
insertion
18-

CCTGGTGCCGCGTGGTAGCACT
GAAATCGTTGCA

with an
N-His
tag

D 6E 6D 2E 3D
GSLVPRSClyA

a thrombin
cleavage
site

12- with
an NHis-tag
and
thrombi
n site

M-H6-D6E6GSG5SLVP
RS-ClyA

Inserting a
5-glycine
linker

RCCACGCGGCACCAGGCTGCCAT
CTTCCTCCTCGTC

Glycine
linker
insertion

FAGCGGTGGCGGTGGTGGCCTGG
TGCCGCGTGGT

RCAGGCCACCACCGCCACCGCTG
CCCTCCTCTTC

Cterminal
His tag
deletion

FCTCTCGAGATGACTGAAATCGTT
GCAG

18- with
an NHis-tag
and
thrombi
n site
6-, 12and 18-

M-H6D 6E 6D 2E 3D
GSG5SLVP
RS-ClyA

Not
applicable

Deleting the
C-terminal
His-tag

RTTTCAGTCATCTCGAGAGCCCAT
ATG

6-, 10-, 12-, 18-21-, and 24- refers to ClyA mutants with 6, 10, 12, 18, 21, 24
negative charges at the N-terminus respectively and a C-terminal His-tag. N-His
tag refers to a Histidine tag at the N-terminal of ClyA. All primer sequences are
presented from left to right or 5’ to 3’, respectively. The forward (F) and reverse
(R) primers are depicted above for every negative mutant.
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